- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
- 10-Q Quarterly report
- 10.1 Future Advance Convertible Promissory Note
- 10.2 Conversion Agreement
- 10.3 Amended and Restated Demand Convertible Promissory Note
- 10.4 Form of Common Stock Purchase Warrant
- 10.5 Form of Unit Purchase Agreement
- 10.6 Placement Agency Agreement
- 10.7 Amendment to Placement Agency Agreement
- 10.8 Patent and Technology License Agreement
- 31.1 Certification
- 32.1 Certification
- Download Excel data file
- View Excel data file
EXHIBIT 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Citius Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Myron Holubiak, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and | |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: May 15, 2017 | By: | /s/ Myron Holubiak | |
Myron Holubiak | |||
Chief Executive Officer, | |||
Principal Executive Officer and Principal Financial Officer |